Selumetinib to prevent tumor growth in NF1 children
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 to 8 years old
- Diagnosed with neurofibromatosis type 1 (NF1)
- No known plexiform neurofibroma (a type of nerve tumor)
- No prior treatment with selumetinib or similar MEK inhibitor medication
- No active cancer or tumor requiring treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests an investigational drug called smethinib (a type of targeted therapy) for people with neurofibromatosis type 1 whose tumors have grown into the brain, spine, or other important organs and cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This study follows up with children who took part in an earlier trial of FCN-159, a drug for a condition called Neurofibromatosis Type 1 (NF1). It aims to see how safe and effective the drug is over a longer period.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.